Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database.

30-day readmission Cirrhosis healthcare cost national readmission database

Journal

Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 20 02 2020
accepted: 23 05 2021
entrez: 23 8 2021
pubmed: 24 8 2021
medline: 24 8 2021
Statut: ppublish

Résumé

Cirrhosis is associated with substantial inpatient morbidity and mortality. This study aimed to determine the trends in 30-day hospital readmission rates among patients with cirrhosis and identify factors associated with these readmissions. We conducted a retrospective analysis of data retrieved from the Nationwide Readmissions Database to determine trends in 30-day readmission for patients discharged with a diagnosis of cirrhosis in 2010 through 2014. Multivariate logistic regression analysis was used to identify predictors of readmission. Among 303,346 patients identified from the database, the 30-day readmission rate for patients with a discharge diagnosis of cirrhosis was 31.4% (n=95,298). The trends in the readmission rates remained steady during the study period. On multivariate analysis, female sex, age 45 years or older, esophagogastroduodenoscopy (EGD) during admission, and disposition to a short-term care facility or skilled nursing facility protected against readmissions. In contrast, coverage by Medicaid insurance, admission during a weekend, nonalcoholic cause of cirrhosis, and history of hepatic encephalopathy and ascites were associated with readmission. We found an exceptionally high 30-day readmission rate in patients with cirrhosis, although it remained stable during the study period. This study identified some modifiable factors such as disposition to a short-term care facility or skilled nursing facility and patients' attendance of alcohol rehabilitation facilities that could decrease the likelihood of readmission and could inform local and national healthcare policymakers.

Sections du résumé

BACKGROUND BACKGROUND
Cirrhosis is associated with substantial inpatient morbidity and mortality. This study aimed to determine the trends in 30-day hospital readmission rates among patients with cirrhosis and identify factors associated with these readmissions.
METHODS METHODS
We conducted a retrospective analysis of data retrieved from the Nationwide Readmissions Database to determine trends in 30-day readmission for patients discharged with a diagnosis of cirrhosis in 2010 through 2014. Multivariate logistic regression analysis was used to identify predictors of readmission.
RESULTS RESULTS
Among 303,346 patients identified from the database, the 30-day readmission rate for patients with a discharge diagnosis of cirrhosis was 31.4% (n=95,298). The trends in the readmission rates remained steady during the study period. On multivariate analysis, female sex, age 45 years or older, esophagogastroduodenoscopy (EGD) during admission, and disposition to a short-term care facility or skilled nursing facility protected against readmissions. In contrast, coverage by Medicaid insurance, admission during a weekend, nonalcoholic cause of cirrhosis, and history of hepatic encephalopathy and ascites were associated with readmission.
CONCLUSIONS CONCLUSIONS
We found an exceptionally high 30-day readmission rate in patients with cirrhosis, although it remained stable during the study period. This study identified some modifiable factors such as disposition to a short-term care facility or skilled nursing facility and patients' attendance of alcohol rehabilitation facilities that could decrease the likelihood of readmission and could inform local and national healthcare policymakers.

Identifiants

pubmed: 34422964
doi: 10.21037/atm-20-1762
pii: atm-09-13-1052
pmc: PMC8339830
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1052

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK083266
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

2021 Annals of Translational Medicine. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/atm-20-1762). The authors have no conflicts of interest to declare.

Références

Am J Gastroenterol. 2016 Jan;111(1):87-92
pubmed: 26729545
Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60
pubmed: 21440669
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Dig Dis Sci. 2018 Sep;63(9):2267-2274
pubmed: 29457210
J Surg Res. 2018 Mar;223:22-28
pubmed: 29433877
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1181-1188.e2
pubmed: 27085758
Am J Gastroenterol. 2019 Jan;114(1):98-106
pubmed: 30333543
N Engl J Med. 2016 Apr 21;374(16):1543-51
pubmed: 26910198
J Clin Gastroenterol. 2013 May-Jun;47(5):e50-4
pubmed: 23090041
Hosp Pract (1995). 2016;44(1):60-9
pubmed: 26782133
Clin Gastroenterol Hepatol. 2011 Oct;9(10):897-901
pubmed: 21782772
Ann Gastroenterol. 2016 Oct-Dec;29(4):515-520
pubmed: 27708520
J Clin Gastroenterol. 2015 Sep;49(8):690-6
pubmed: 25291348
BMJ Open Gastroenterol. 2017 Sep 11;4(1):e000161
pubmed: 28944074
Heart Rhythm. 2018 May;15(5):708-715
pubmed: 29317316
Dig Dis. 2017;35(5):433-438
pubmed: 28245467
BMJ. 2018 Feb 27;360:k497
pubmed: 29487063
J Clin Gastroenterol. 2017 Oct;51(9):839-844
pubmed: 28383303
Gastroenterology. 2018 Sep;155(3):719-729.e4
pubmed: 29802851
Dig Liver Dis. 2017 Aug;49(8):903-909
pubmed: 28410915
JBI Database System Rev Implement Rep. 2017 Aug;15(8):2060-2086
pubmed: 28800056
Hepatology. 2016 Dec;64(6):2165-2172
pubmed: 27696493
Hepatol Commun. 2018 Jan 18;2(2):188-198
pubmed: 29404526
Intern Med J. 2014 Sep;44(9):865-72
pubmed: 24893971
Clin Gastroenterol Hepatol. 2016 May;14(5):753-9
pubmed: 26407750
World J Gastroenterol. 2017 Oct 7;23(37):6868-6876
pubmed: 29085229
Gastroenterology. 2012 Jul;143(1):17-9
pubmed: 22626503
J Intensive Care Med. 2019 Nov-Dec;34(11-12):1017-1022
pubmed: 28820039
PLoS One. 2013;8(1):e55140
pubmed: 23383085
South Med J. 2015 Nov;108(11):682-7
pubmed: 26539950

Auteurs

Sushil Kumar Garg (SK)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Hemant Goyal (H)

Mercer University School of Medicine, Macon, GA, USA.

Itegbemie Obaitan (I)

Department of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN, USA.

Pir Ahmad Shah (PA)

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Shashank Sarvepalli (S)

Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.

Loretta Lynn Jophlin (LL)

Division of Gastroenterology-Hepatology, University of Nebraska Medical Center, Omaha, NE, USA.

Dupinder Singh (D)

Department of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN, USA.

Sumeet Asrani (S)

Baylor University Medical Center, Baylor Scott and White, Dallas, TX, USA.

Patrick S Kamath (PS)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Michael D Leise (MD)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Classifications MeSH